Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8VP6R
|
|||
| Drug Name |
PF-06865571
|
|||
| Synonyms |
Ervogastat; Ervogastat [INN]; 2186700-33-2; BSOIY5AKQW; PF-06865571; UNII-BSOIY5AKQW; 2-(5-((3-Ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-((3S)-oxolan3-yl)pyrimidine-5-carboxamide; 5-Pyrimidinecarboxamide, 2-(5-((3-ethoxy-2-pyridinyl)oxy)-3-pyridinyl)-N-((3S)-tetrahydro-3-furanyl)-; CHEMBL4760665; SCHEMBL19875384; GTPL12241; US10071992, Example 1; BDBM276750; EX-A7128; US10071992, Example 3.4; AKOS040759712; AT28030; compound 6 [PMID: 34635855]; PF06865571; 2-[5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide; (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 2 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21N5O4
|
|||
| Canonical SMILES |
CCOC1=C(N=CC=C1)OC2=CN=CC(=C2)C3=NC=C(C=N3)C(=O)NC4CCOC4
|
|||
| InChI |
InChI=1S/C21H21N5O4/c1-2-29-18-4-3-6-23-21(18)30-17-8-14(9-22-12-17)19-24-10-15(11-25-19)20(27)26-16-5-7-28-13-16/h3-4,6,8-12,16H,2,5,7,13H2,1H3,(H,26,27)/t16-/m0/s1
|
|||
| InChIKey |
UKBQFBRPXKGJPY-INIZCTEOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Diacylglycerol O-acyltransferase 2 (DGAT2) | Target Info | Inhibitor | [2] |
| BioCyc | Triacylglycerol biosynthesis | |||
| KEGG Pathway | Glycerolipid metabolism | |||
| Metabolic pathways | ||||
| Fat digestion and absorption | ||||
| Reactome | Acyl chain remodeling of DAG and TAG | |||
| Triglyceride Biosynthesis | ||||
| WikiPathways | Triacylglyceride Synthesis | |||
| Glycerophospholipid biosynthesis | ||||
| Fatty acid, triacylglycerol, and ketone body metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04321031) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3. U.S.National Institutes of Health. | |||
| REF 2 | Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis. J Med Chem. 2022 Nov 24;65(22):15000-15013. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.